SCHEMBL5598393

SCHEMBL5598393

CC(C)(C)OC(=O)NCc1ccc(/C=C/C(=O)O)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.48
NAMPT P43490 2/20 0.46
GAA P10253 1/20 0.46
PPARG P37231 1/20 0.46
PPARA Q07869 1/20 0.46
MMP1 P03956 2/20 0.46
MMP2 P08253 2/20 0.46
MMP9 P14780 2/20 0.46
THRB P10828 1/20 0.45
ATM Q13315 1/20 0.45
HDAC1 Q13547 1/20 0.45
AKR1C4 P17516 3/20 0.44
AKR1C3 P42330 3/20 0.44
AKR1C2 P52895 1/20 0.44
AKR1C1 Q04828 1/20 0.44
LMNA P02545 1/20 0.44
CA1 P00915 2/20 0.44
CA2 P00918 1/20 0.44
CYP26A1 O43174 1/20 0.43
CYP26B1 Q9NR63 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5598396 1.00 L3MBTL1 (0.48) L3MBTL1NAMPTGAAPPARGPPARA
SCHEMBL3674926 0.88 CA1 (0.51) L3MBTL1NAMPTGAAPPARGPPARA
SCHEMBL27908341 0.88 HDAC3 (0.56) HDAC1
SCHEMBL1165045 0.88 CA1 (0.51) L3MBTL1NAMPTGAAPPARGPPARA
SCHEMBL8985040 0.85 MMP1 (0.51) MMP1MMP2MMP9AKR1C3CA1
SCHEMBL8985043 0.85 MMP1 (0.51) MMP1MMP2MMP9AKR1C3CA1
SCHEMBL30944751 0.84 CA12 (0.55) L3MBTL1NAMPTGAAAKR1C3LMNA
SCHEMBL6987937 0.84 CA12 (0.55) L3MBTL1NAMPTGAAAKR1C3LMNA
SCHEMBL3180689 0.83 L3MBTL1 (0.61) L3MBTL1NAMPTGAAHDAC1CA1
SCHEMBL208544 0.82 EPHX2 (0.57) L3MBTL1NAMPTGAAATMHDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111039875-A HDAC/ALK double-target-point inhibitor and preparation method and application thereof 重庆医科大学 2020-04-21 CN disclosed
EP-1654247-B1 ALKYNYL ARYL CARBOXAMIDES MERCK SERONO SA (CH) 2010-01-20 EP disclosed
US-7589232-B2 Alkynyl aryl carboxamides LABORATORIES SERONO S.A. (CH) 2009-09-15 US disclosed
US-7589232-B2 Alkynyl aryl carboxamides LABORATORIES SERONO S.A. (CH) 2009-09-15 US disclosed
US-20070105913-A1 Alkynyl aryl carboxamides APPLIED RESEARCH SYSTEMS ARS HOLDINGS N.V. (NL) 2007-05-10 US disclosed
US-20070105913-A1 Alkynyl aryl carboxamides APPLIED RESEARCH SYSTEMS ARS HOLDINGS N.V. (NL) 2007-05-10 US disclosed
US-20070105913-A1 Alkynyl aryl carboxamides APPLIED RESEARCH SYSTEMS ARS HOLDINGS N.V. (NL) 2007-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105913-A1 Alkynyl aryl carboxamides ECHS1, IRS1, HCCS L3MBTL1 3340/4885NAMPT 3212/4885GAA 2263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.